JournalsHub
.online
Find My Journal
RK

Robin Kate Kelley

University of California, San Francisco US

ORCID 0000-0002-1984-2430
509
Publications
79,235
Citations
94
H-Index
215
i10-Index
13.93
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex . OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Hepatocellular carcinoma OA
Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva, Amit G. Singal, Eli Pikarsky +5 more
Nature Reviews Disease Primers 2021
6,249
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update OA
María Reig, Alejandro Forner, Jordi Rimola, Joana Ferrer, Marta Burrel +11 more
Journal of Hepatology 2021
3,985
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara +54 more
The Lancet Oncology 2018
2,505
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma OA
Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Lorenza Rimassa +17 more
New England Journal of Medicine 2018
2,308
Cholangiocarcinoma — evolving concepts and therapeutic strategies OA
Sumera I. Ilyas, Shahid A. Khan, Christopher L. Hallemeier, Robin Kate Kelley, Gregory J. Gores
Nature Reviews Clinical Oncology 2017
1,678

Publications

470 total

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial PDF

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse et al. - The Lancet, 2023
Cited by 948 OpenAlex

Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma PDF

Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque, Juan W. Valle, Chigusa Morizane et al. - New England Journal of Medicine, 2023
Cited by 499 OpenAlex

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma PDF

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo, Stephen L. Chan, Robin Kate Kelley et al. - NEJM Evidence, 2022
Cited by 1,349 OpenAlex

Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PDF

Arndt Vogel, John Bridgewater, Julien Edeline, Robin Kate Kelley, Heinz‐Josef Klümpen et al. - Annals of Oncology, 2022
Cited by 582 OpenAlex

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial PDF

Robin Kate Kelley, Lorenza Rimassa, Ann‐Lii Cheng, Ahmed O. Kaseb, Shukui Qin et al. - The Lancet Oncology, 2022
Cited by 505 OpenAlex

Hepatocellular carcinoma PDF

Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva, Amit G. Singal, Eli Pikarsky et al. - Nature Reviews Disease Primers, 2021
Cited by 6,249 OpenAlex

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update PDF

María Reig, Alejandro Forner, Jordi Rimola, Joana Ferrer, Marta Burrel et al. - Journal of Hepatology, 2021
Cited by 3,985 OpenAlex

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology PDF

Al B. Benson, Michael I. D’Angelica, Daniel E. Abbott, Daniel A. Anaya, Robert A. Anders et al. - Journal of the National Comprehensive Cancer Network, 2021
Cited by 1,021 OpenAlex

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study PDF

Ghassan K. Abou‐Alfa, Teresa Macarulla, Milind Javle, Robin Kate Kelley, Sam Joseph Lubner et al. - The Lancet Oncology, 2020
Cited by 1,034 OpenAlex

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

John D. Gordan, Erin B. Kennedy, Ghassan K. Abou‐Alfa, Muhammad Shaalan Beg, Steven T. Brower et al. - Journal of Clinical Oncology, 2020
Cited by 609 OpenAlex

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis (189) Cholangiocarcinoma and Gallbladder Cancer Studies (153) Pancreatic and Hepatic Oncology Research (135) Cancer Genomics and Diagnostics (91) Cancer Immunotherapy and Biomarkers (69)

Frequent Co-Authors

RI
Richard S. Finn
6 joint publications
ST
Stephen L. Chan
6 joint publications
JU
Julien Edeline
5 joint publications
AN
Ann‐Lii Cheng
5 joint publications
GH
Ghassan K. Abou‐Alfa
5 joint publications
IV
Ivan Borbath
4 joint publications

Affiliations

Roche (Switzerland)
CH 2021 - 2021
Novartis (Switzerland)
CH 2019 - 2019
Prisma Health
US 1997 - 1997
Memorial Sloan Kettering Cancer Center
US 2016 - 2016
Humanitas University
IT 2021 - 2021

External Profiles

OpenAlex Profile Search Semantic Scholar ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now